ATE419008T1 - Adjuvante zusammensetzung und anwendungsverfahren dafür - Google Patents

Adjuvante zusammensetzung und anwendungsverfahren dafür

Info

Publication number
ATE419008T1
ATE419008T1 AT05747242T AT05747242T ATE419008T1 AT E419008 T1 ATE419008 T1 AT E419008T1 AT 05747242 T AT05747242 T AT 05747242T AT 05747242 T AT05747242 T AT 05747242T AT E419008 T1 ATE419008 T1 AT E419008T1
Authority
AT
Austria
Prior art keywords
vaccine
adjuvant composition
gammadeltat
directed
present
Prior art date
Application number
AT05747242T
Other languages
English (en)
Inventor
Jerome Tiollier
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE419008T1 publication Critical patent/ATE419008T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
AT05747242T 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür ATE419008T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56495904P 2004-04-26 2004-04-26
US62906904P 2004-11-18 2004-11-18

Publications (1)

Publication Number Publication Date
ATE419008T1 true ATE419008T1 (de) 2009-01-15

Family

ID=34969994

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05747242T ATE419008T1 (de) 2004-04-26 2005-04-25 Adjuvante zusammensetzung und anwendungsverfahren dafür

Country Status (8)

Country Link
US (1) US20070218086A1 (de)
EP (1) EP1761278B1 (de)
JP (1) JP2007534743A (de)
AT (1) ATE419008T1 (de)
AU (1) AU2005235271A1 (de)
CA (1) CA2564562A1 (de)
DE (1) DE602005012097D1 (de)
WO (1) WO2005102385A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0212666D0 (en) * 2002-05-31 2002-07-10 Secr Defence Immunogenic sequences
WO2005077411A2 (en) * 2004-02-10 2005-08-25 Innate Pharma Composition and method for the treatment of carcinoma
WO2006067635A2 (en) * 2004-12-20 2006-06-29 Innate Pharma S.A. USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
WO2006103568A2 (en) * 2005-03-22 2006-10-05 Innate Pharma NEW CLASS OF Ϝδ T CELLS ACTIVATORS AND USE THEREOF
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
ITMI20060366A1 (it) * 2006-03-01 2007-09-02 C4T S C A R L Composti organo tiopirosfosfati metodo per prepararli e composizioni che li contengono
EP1878440A1 (de) * 2006-07-13 2008-01-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Verfahren und zusammensetzungen zur erhöhung der effizienz von therapeutischen antikörpern mit gamma delta zellaktivatoren
EP2040744B1 (de) * 2006-07-25 2016-03-09 The Secretary of State for Defence Francisella lebendvakzine
EP2123285A1 (de) * 2008-05-21 2009-11-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleosid-Phosphorantigene zur Verwendung in der VGAMMA9VDELTA2-T-Zellen-vermittelten Therapie
WO2010029062A1 (en) 2008-09-10 2010-03-18 Innate Pharma Novel polymorphic form of chdmapp, method of preparation thereof, and pharmaceutical composition comprising same
EP2337847B1 (de) * 2008-09-29 2015-12-02 Cadila Pharmaceuticals Ltd. Impfstoffadjuvanzien
GB0901411D0 (en) * 2009-01-29 2009-03-11 Secr Defence Treatment
WO2014145038A1 (en) * 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
KR102451441B1 (ko) * 2020-06-25 2022-10-12 대한민국 신규 면역증강제 및 이를 포함하는 백신 조성물
WO2021261635A1 (ko) * 2020-06-26 2021-12-30 대한민국(농림축산식품부 농림축산검역본부장) 신규 면역증강제 및 이를 포함하는 백신 조성물
CA3223936A1 (en) * 2021-06-28 2023-01-05 Ronald Christiaan Elgersma Conjugates comprising phosphoantigens and their use in therapy
GB202114311D0 (en) * 2021-10-06 2021-11-17 Molecular Attraction Ab New compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5639653A (en) 1993-07-19 1997-06-17 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva Universtiy Method for proliferating Vγ2Vδ2 T cells
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1998050567A1 (en) 1997-05-02 1998-11-12 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
BE1011282A3 (fr) * 1997-07-14 1999-07-06 Solvay Composition a base de polyethylene et procede de fabrication d'objets faconnes a partir de la composition.
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
FR2782721B1 (fr) * 1998-09-01 2000-11-03 Inst Nat Sante Rech Med Nouveaux composes phosphohalohydrines, procede de fabrication et applications
FR2782722B1 (fr) * 1998-09-01 2001-01-12 Inst Nat Sante Rech Med Nouveaux composes phosphoepoxydes, procede de fabrication et applications
DK1408984T3 (da) 2001-07-20 2009-02-09 Bioagency Ag Organofosforforbindelser til aktivering af gamma/delta T celler
CA2453880A1 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003038072A1 (en) * 2001-10-31 2003-05-08 Universite Libre De Bruxelles Generation and use of new types of dendritic cells
FR2833266B1 (fr) * 2001-12-11 2004-10-22 Mayoly Spindler Lab Nouveaux derives phosphonates, leur procede de preparation, leur utilisation comme modulateurs de l'activite des lymphocytes tgamma9 delta2
DE60233576D1 (de) 2002-12-02 2009-10-15 Innate Pharma Interleukin-2 und Gamma Delta T Zellaktivator enthaltende Zusammensetzungen und deren Verwendungen
WO2005021708A2 (en) * 2003-05-16 2005-03-10 University Of Maryland Biotechnology Institute Bisphosphonates for prophylaxis and therapy against bioterrorism agents
EP1689758A2 (de) 2003-12-02 2006-08-16 Innate Pharma Neue klasse von aktivatoren von gamma-delta-t-zellen und deren verwendung

Also Published As

Publication number Publication date
CA2564562A1 (en) 2005-11-03
EP1761278B1 (de) 2008-12-31
EP1761278A1 (de) 2007-03-14
DE602005012097D1 (de) 2009-02-12
JP2007534743A (ja) 2007-11-29
US20070218086A1 (en) 2007-09-20
WO2005102385A1 (en) 2005-11-03
AU2005235271A1 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür
EA200800812A1 (ru) Композиции антитела против cd3
ATE426412T1 (de) Adjuvante influenza-vakzine
EA200700702A1 (ru) Аналоги локсапина и способы их применения
IL244803B (en) Human anti-beta antibodies and their use
NO20083895L (no) Anti-IGF-1R human monoklonalantibody formulering
EA200801427A1 (ru) Молекулы антитела со специфической активностью в отношении интерлейкина-6 (ил-6) человека
IS7133A (is) Afleiða beta-amyloid - T-frumu-mótefnavísisbóluefni
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
NO20070699L (no) Spesielle aminoalkylglukosaminidfosfatforbindelser og deres anvendelse
EA200701305A1 (ru) Иммуногенные композиции, содержащие циклические пептиды, полученные из бета-амилоидного пептида
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
MX2007002787A (es) Adyuvante de glicosilceramida para antigenos de sacarido.
ATE497492T1 (de) Reinigung von montelukast
DK1668001T3 (da) Substituerede heteroarylbenzofuransyrer
WO2006067635A3 (en) USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
NO20062579L (no) Preparater som omfatter melittin-avledede peptider og fremgangsmate for styrking av immunresponser mot malantigener
EA200702092A1 (ru) Липосомная композиция для индукции иммунитета
AR059851A1 (es) Anticuerpos de la egfl7 y metodos de uso
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
ATE458496T1 (de) Hiv-vakzine und anwendungsverfahren
ATE422367T1 (de) Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür
EA201200538A1 (ru) Арабиногалактан для повышения приобретенного иммунного ответа
WO2006088997A3 (en) Adjuvant activities of b pentamers of lt-iia and lt-iib enterotoxin

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1761278

Country of ref document: EP

REN Ceased due to non-payment of the annual fee